Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 May;44(5):1126-1128.
doi: 10.1111/liv.15888.

PRO-C3, liver fibrosis and CKD: The plot thickens

Amedeo Lonardo  1
Affiliations
Editorial

PRO-C3, liver fibrosis and CKD: The plot thickens

Amedeo Lonardo. Liver Int. 2024 May.
No abstract available

Keywords: ADAPT; Agile 3+; MAFLD, NAFLD, PERIOD score; collagen; propeptides; steatotic liver disease.

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Zheng MH, Tang, LJ, Sun DQ, et al. Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort. Liver International.
    1. Daniels SJ, Leeming DJ, Eslam M, et al. ADAPT: an algorithm incorporating PRO‐C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology. 2019;69:1075‐1086.
    1. Sanyal AJ, Foucquier J, Younossi ZM, et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan‐based Agile scores. J Hepatol. 2023;78:247‐259.
    1. Stefan N, Lonardo A, Targher G. Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases. Nat Rev Gastroenterol Hepatol. 2023. doi:10.1038/s41575-023-00880-2
    1. Nabi O, Lapidus N, Boursier J, et al. The NAFLD burden on mortality and morbidities in general population: a community‐based longitudinal study (NASH‐CO study). Liver Int. 2023;43:2096‐2106.

LinkOut - more resources